BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 36728908)

  • 1. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
    Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
    Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
    Lim SM; Fujino T; Kim C; Lee G; Lee YH; Kim DW; Ahn JS; Mitsudomi T; Jin T; Lee SY
    Clin Cancer Res; 2023 Aug; 29(16):3004-3016. PubMed ID: 37249619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
    Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
    Park W; Wei S; Xie CL; Han JH; Kim BS; Kim B; Jin JS; Yang ES; Cho MK; Ryu D; Yang HX; Bae SJ; Ha KT
    Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Kogure Y; Tachihara M; Fujimoto D; Yamaguchi K; Hamaguchi N; Okamoto I; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2021 Jul; 22(4):376-380. PubMed ID: 33612406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
    Yamaguchi O; Kasahara N; Soda H; Imai H; Naruse I; Yamaguchi H; Itai M; Taguchi K; Uchida M; Sunaga N; Maeno T; Minato K; Tomono H; Ogawara D; Mukae H; Miura Y; Shiono A; Mouri A; Kagamu H; Kaira K
    Sci Rep; 2023 Nov; 13(1):20848. PubMed ID: 38012343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
    Takeda M; Shimokawa M; Nakamura A; Nosaki K; Watanabe Y; Kato T; Hayakawa D; Tanaka H; Takahashi T; Oki M; Tachihara M; Fujimoto D; Hayashi H; Yamaguchi K; Yamamoto S; Iwama E; Azuma K; Hasegawa K; Yamamoto N; Nakagawa K
    Lung Cancer; 2023 Mar; 177():44-50. PubMed ID: 36731290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
    Asahina H; Tanaka K; Morita S; Maemondo M; Seike M; Okamoto I; Oizumi S; Kagamu H; Takahashi K; Kikuchi T; Isobe T; Sugio K; Kobayashi K
    Clin Lung Cancer; 2021 Mar; 22(2):147-151. PubMed ID: 33199228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.
    Guo Q; Feng W; Hu S; Ye J; Wang S; Su L; Zhang Y; Zhang D; Zhang W; Xu J; Wei Y
    Medicine (Baltimore); 2023 Aug; 102(34):e34545. PubMed ID: 37653755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
    Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
    J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.
    Falk M; Schatz S; Reich FPM; Schmidt S; Galster M; Tiemann M; Ficker JH; Brueckl WM
    Curr Oncol; 2023 Sep; 30(10):8865-8871. PubMed ID: 37887540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.
    Elkrief A; Makhnin A; Moses KA; Ahn LS; Preeshagul IR; Iqbal AN; Hayes SA; Plodkowski AJ; Paik PK; Ladanyi M; Kris MG; Riely GJ; Michor F; Yu HA
    Clin Cancer Res; 2023 Apr; 29(8):1423-1428. PubMed ID: 36729110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of osimertinib to discover new potent EGFR
    Xi XX; Zhao HY; Mao YZ; Xin M; Zhang SQ
    Eur J Med Chem; 2023 Dec; 261():115865. PubMed ID: 37839342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib with or without Chemotherapy in
    Planchard D; Jänne PA; Cheng Y; Yang JC; Yanagitani N; Kim SW; Sugawara S; Yu Y; Fan Y; Geater SL; Laktionov K; Lee CK; Valdiviezo N; Ahmed S; Maurel JM; Andrasina I; Goldman J; Ghiorghiu D; Rukazenkov Y; Todd A; Kobayashi K;
    N Engl J Med; 2023 Nov; 389(21):1935-1948. PubMed ID: 37937763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.
    Rotow JK; Lee JK; Madison RW; Oxnard GR; Jänne PA; Schrock AB
    J Thorac Oncol; 2024 Feb; 19(2):227-239. PubMed ID: 37806383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
    Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
    Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance.
    Zhu Y; Ye X; Shen H; Li J; Cai Z; Min W; Hou Y; Dong H; Wu Y; Wang L; Wang X; Xiao Y; Yang P
    J Med Chem; 2023 Nov; 66(21):14633-14652. PubMed ID: 37885208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC.
    Yamaguchi T; Masago K; Sasaki E; Kuroda H; Matsushita H; Horio Y
    Cancer Genet; 2024 Jan; 280-281():13-16. PubMed ID: 38128381
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
    Tan L; Brown C; Mersiades A; Lee CK; John T; Kao S; Newnham G; O'Byrne K; Parakh S; Bray V; Jasas K; Yip S; Wong SQ; Ftouni S; Guinto J; Chandrashekar S; Clarke S; Pavlakis N; Stockler MR; Dawson SJ; Solomon BJ
    Nat Commun; 2024 Feb; 15(1):1823. PubMed ID: 38418463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].
    Messekher M; François H; Denis MG; Ferrer-Lopez P; Bost-Bezeaud F; Mazières J; Parrat E
    Rev Mal Respir; 2024 Jun; 41(6):451-454. PubMed ID: 38796386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.